NEJM This Week NEJM This Week — September 4, 2025
10 snips
Sep 3, 2025 Dive into a compelling discussion on innovative obesity treatments combining GLP-1 and GIP receptor therapies, showcasing significant weight loss. Explore cutting-edge diabetes therapies, including stem cell advancements, and the effective use of benzathine penicillin G for early syphilis. Discover groundbreaking insights on monoclonal antibodies in Heparin-Induced Thrombocytopenia, along with evolving management strategies for acute type B aortic dissection. Unpack the challenges and opportunities of corporatization in healthcare, especially in relation to physician-scientist training and drug innovation in China.
AI Snips
Chapters
Transcript
Episode notes
Monthly Peptide Conjugate Yields Large Weight Loss
- Meritibard-Cafra, a long-acting peptide–antibody conjugate, produced up to 16.2% mean weight loss at 52 weeks in non-diabetic participants.
- Gastrointestinal side effects were common but reduced with gradual dose escalation and lower starting doses.
Diabetes Limits Weight Response And Raises Access Issues
- Participants with type 2 diabetes lost less weight (up to 12.3%) and had HbA1c reductions up to 1.6 percentage points.
- Editorialists highlight cost and coverage as major nonmedical barriers to long-term access and adherence.
Zimislicel Restores Islet Function In Small Trial
- Trevor Reichman reported a Phase 1–2 study of Zimislicel, stem cell–derived fully differentiated islets, in 14 people with type 1 diabetes and severe hypoglycemia.
- The small study suggested restoration of physiologic islet function and prevented severe hypoglycemia in full-dose recipients.